Item does not contain fulltextINTRODUCTION: Long-term survival after heart transplantation (HTx) is hampered by cardiac allograft vasculopathy (CAV). Better understanding of the pathophysiological mechanisms of CAV might have considerable consequences for therapeutic approaches in the future. The aim of the present study was to investigate the histological phenotypes of CAV in relation with clinical patient characteristics. METHODS AND RESULTS: Coronary cross-sections from 51 HTx patients were obtained at autopsy. CAV was observed in 42 patients (82%). Three histological CAV phenotypes were identified (H-CAV 1-3). No CAV (H-CAV 0) is as seen in normal coronary arteries; intimal thickening consisting of a layer of longitudinal oriented smoot...
Cardiac transplantation is currently the preferred choice of treatment for end-stage cardiac disease...
Heart transplantation (HTx) is the treatment of choice for patients with refractory end-stage heart ...
Jacob C Jentzer,1 Gavin W Hickey,1 Sameer J Khandhar2,3 1Heart and Vascular Institute, Universi...
Introduction: Long-term survival after heart transplantation (HTx) is hampered by cardiac allograft ...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
The major cause of late death in cardiac transplant recipients is cardiac allograft vasculopathy, al...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipien...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Cardiac transplantation is currently the preferred choice of treatment for end-stage cardiac disease...
Heart transplantation (HTx) is the treatment of choice for patients with refractory end-stage heart ...
Jacob C Jentzer,1 Gavin W Hickey,1 Sameer J Khandhar2,3 1Heart and Vascular Institute, Universi...
Introduction: Long-term survival after heart transplantation (HTx) is hampered by cardiac allograft ...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
The major cause of late death in cardiac transplant recipients is cardiac allograft vasculopathy, al...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipien...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Background Cardiac allograft vasculopathy (CAV) is a multifactorial disease and a major cause of gra...
Cardiac transplantation is currently the preferred choice of treatment for end-stage cardiac disease...
Heart transplantation (HTx) is the treatment of choice for patients with refractory end-stage heart ...
Jacob C Jentzer,1 Gavin W Hickey,1 Sameer J Khandhar2,3 1Heart and Vascular Institute, Universi...